Department of Laboratory Medicine,
Deptartment of Bioengineering and Therapeutic Sciences
Arun P. Wiita has not added Biography.
If you are Arun P. Wiita and would like to personalize this page please email our Author Liaison for assistance.
Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics.
Cell systems Jun, 2017 | Pubmed ID: 28578850
False positive cell free DNA screening for microdeletions due to non-pathogenic copy number variants.
Prenatal diagnosis Jun, 2016 | Pubmed ID: 27061292
False negative fetal cell free DNA screening for microdeletion syndromes in the presence of an unbalanced translocation involving monosomy 4p.
Prenatal diagnosis Apr, 2017 | Pubmed ID: 28207935
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.
Molecular cancer therapeutics Nov, 2017 | Pubmed ID: 28878026
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Haematologica Jul, 2018 | Pubmed ID: 29622655
Seeking Convergence and Cure with New Myeloma Therapies.
Trends in cancer Aug, 2018 | Pubmed ID: 30064664
ClinTAD: a tool for copy number variant interpretation in the context of topologically associated domains.
Journal of human genetics May, 2019 | Pubmed ID: 30765865
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.
Leukemia Mar, 2020 | Pubmed ID: 31595037
X-linked duplication copy number variation in a familial overgrowth condition.
American journal of medical genetics. Part C, Seminars in medical genetics Dec, 2019 | Pubmed ID: 31762227
The LC3-conjugation machinery specifies the loading of RNA-binding proteins into extracellular vesicles.
Nature cell biology Feb, 2020 | Pubmed ID: 31932738
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Leukemia Oct, 2020 | Pubmed ID: 32123307
Prevalence of Partial Hydatidiform Mole in Products of Conception From Gestations With Fetal Triploidy Merits Reflex Genotype Testing Independent of the Morphologic Appearance of the Chorionic Villi.
The American journal of surgical pathology Jun, 2020 | Pubmed ID: 32205485
Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer.
Advances in experimental medicine and biology , 2020 | Pubmed ID: 32297217
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.
Nature communications Apr, 2020 | Pubmed ID: 32321912
Signalling input from divergent pathways subverts B cell transformation.
Nature Jul, 2020 | Pubmed ID: 32699415
IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.
Nature Dec, 2020 | Pubmed ID: 33149299
Author Correction: IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.
Nature Apr, 2021 | Pubmed ID: 33712811
Surface Proteomics Reveals CD72 as a Target for -Evolved Nanobody-Based CAR-T Cells in -Rearranged B-ALL.
Cancer discovery Aug, 2021 | Pubmed ID: 33727310
GRASP55 restricts early-stage autophagy and regulates spatial organization of the early secretory network.
Biology open Oct, 2021 | Pubmed ID: 34533192
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Nature communications Jul, 2022 | Pubmed ID: 35840578
Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
Cell chemical biology Aug, 2022 | Pubmed ID: 35853457
ECM dimensionality tunes actin tension to modulate endoplasmic reticulum function and spheroid phenotypes of mammary epithelial cells.
The EMBO journal Sep, 2022 | Pubmed ID: 35880301
TRAPPC9-related neurodevelopmental disorder: Report of a homozygous deletion in TRAPPC9 due to paternal uniparental isodisomy.
American journal of medical genetics. Part A Apr, 2023 | Pubmed ID: 36574751
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유